In this context, we tried to briefly summarize the accumulating evidence and recommendations for the management of IBD in the context of the COVID-19 pandemic
📌 3 Key Takeaways
🎯
Objective & Hypothesis:The COVID-19 pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2, has resulted in high mortality and morbidity worldwide and is still a growing problem.
📊
Key Findings & Data:Despite the accumulating evidence, there is still a lack of knowledge about the impact of COVID-19 on IBD patients, especially those who are under immunosuppressive treatment.
💡
Conclusion & Impact:In this context, we tried to briefly summarize the accumulating evidence and recommendations for the management of IBD in the context of the COVID-19 pandemic
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Özet
The COVID-19 pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2, has resulted in high mortality and morbidity worldwide and is still a growing problem. Inflammatory bowel disease (IBD) is a chronic inflammatory disease for which a substantial number of patients are treated with immunosuppressive medications, either occasionally or long-term. Despite the accumulating evidence, there is still a lack of knowledge about the impact of COVID-19 on IBD patients, especially those who are under immunosuppressive treatment. Moreover, following the emergence of several COVID vaccines, there are concerns regarding vaccine effectiveness and possible side effects in such patients. In this context, we tried to briefly summarize the accumulating evidence and recommendations for the management of IBD in the context of the COVID-19 pandemic
🔖
Cite This Article
TÖRÜNER, M., KALKAN, İ. H., AKYÜZ, F., TEZEL, A., ÇELİK, A. F. (2021). Turkish IBD Organization’s Position Statement on Inflammatory Bowel Disease Management Recommendations During COVID-19 Pandemic. Turkish Journal of Gastroenterology, Cilt: 32 - Sayı: 6, 488–492. https://ajindex.com/articles/410013
Wang D, Hu B, Hu C et al. Clinical characteristics of 138 hospitalized patients With 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020
323(11):1061-1069. [CrossRef] 2. Anon, world health organization, dirs.General’s opening remarks at the media briefing on COVID-19. https://www.who.int/dg/spee ches/detail/who-director-general-sopening-rema rks- at -th emedia- briefing-on-covid-19-23-marc h-2020. 2020. 3. Anon. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). 2020 https://gisanddata.maps.arcgis.com/apps/dashboards/bda 7594740fd40299423467b48e9ecf6. 4. She J, Liu L, Liu W. COVID-19 epidemic: disease characteristics in children. J Med Virol. 2020
92(7):747-754. [CrossRef] 5. Wang W., Xu Y, Gao R et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020
323(18):1843-1844. [CrossRef] 6. Huang C., Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020
395(10223):497-506. [CrossRef] 7. Guan W.J., Ni ZY, Hu Y et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020
382(18):1708-1720. [CrossRef] 8. Hajifathalian K., Krisko T, Mehta A et al. Gastrointestinal and hepatic manifestations of 2019 novel coronavirus disease in a large cohort of infected patients From New York: clinical implications. Gastroenterology. 2020
159(3):1137-1140.e2. [CrossRef] 9. Kluytmans-van den Bergh M.F.Q., Buiting AGM, Pas SD et al. Prevalence and clinical presentation of health care workers With symptoms of coronavirus disease 2019 in 2 Dutch hospitals During an early phase of the pandemic. JAMA Netw Open. 2020
3(5):e209673. [CrossRef] 10. Pan L., Mu M, Yang P et al. Clinical characteristics of COVID-19 patients With digestive symptoms in Hubei, China: A descriptive, cross-sectional, multicenter study. Am J Gastroenterol. 2020
115(5):766-773. [CrossRef] 11. Zhou F., Yu T, Du R et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020
395(10229):1054-1062. [CrossRef] 12. Zhu N., Zhang D, Wang W et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020
382(8):727-733. [CrossRef] 13. Chan J.F., Yuan S, Kok KH et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-toperson transmission: a study of a family cluster. Lancet. 202